Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

A Study to Evaluate the Efficacy and Safety of LZM012

NCT06110676 ·Status: RECRUITING ·Phase: PHASE3

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

NCT07130604 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06077331 ·Status: RECRUITING ·Phase: PHASE2

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06278350 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

NCT07326813 ·Status: RECRUITING ·Phase: PHASE3

The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis

NCT01504113 ·Status: UNKNOWN

A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study

NCT02413229 ·Status: COMPLETED ·Phase: PHASE2

Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects

NCT06126718 ·Status: COMPLETED ·Phase: PHASE1

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

NCT04428411 ·Status: COMPLETED

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

NCT07243782 ·Status: RECRUITING

Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

NCT04239859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

NCT05650060 ·Status: COMPLETED

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

NCT01493518 ·Status: TERMINATED ·Phase: PHASE1

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

NCT01961609 ·Status: COMPLETED ·Phase: PHASE3

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

NCT06779136 ·Status: RECRUITING ·Phase: PHASE3

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers

NCT07254325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

NCT05730725 ·Status: COMPLETED ·Phase: PHASE2

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

NCT06844799 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis

NCT06811558 ·Status: NOT_YET_RECRUITING ·Phase: NA

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

NCT06176508 ·Status: RECRUITING ·Phase: PHASE2

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

NCT04167462 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis

NCT03265613 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

NCT01094093 ·Status: COMPLETED ·Phase: PHASE1

A Phase 2 Study of HB0017 in Psoriasis Patients

NCT06592274 ·Status: RECRUITING ·Phase: PHASE2

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

NCT05734482 ·Status: COMPLETED ·Phase: PHASE1